Physiological and proteomic profiles of Trypanosoma brucei rhodesiense parasite isolated from suramin responsive and non-responsive HAT patients in Busoga, Uganda
- PMID: 33588295
- PMCID: PMC7895675
- DOI: 10.1016/j.ijpddr.2021.02.001
Physiological and proteomic profiles of Trypanosoma brucei rhodesiense parasite isolated from suramin responsive and non-responsive HAT patients in Busoga, Uganda
Abstract
Human African Trypanosomiasis (HAT) is a disease of major economic importance in Sub-Saharan Africa. The HAT is caused by Trypanosoma brucei rhodesiense (Tbr) parasite in eastern and southern Africa, with suramin as drug of choice for treatment of early stage of the disease. Suramin treatment failures has been observed among HAT patients in Tbr foci in Uganda. In this study, we assessed Tbr parasite strains isolated from HAT patients responsive (Tbr EATRO-232) and non-responsive (Tbr EATRO-734) to suramin treatment in Busoga, Uganda for 1) putative role of suramin resistance in the treatment failure 2) correlation of suramin resistance with Tbr pathogenicity and 3) proteomic pathways underpinning the potential suramin resistance phenotype in vivo. We first assessed suramin response in each isolate by infecting male Swiss white mice followed by treatment using a series of suramin doses. We then assessed relative pathogenicity of the two Tbr isolates by assessing changes pathogenicity indices (prepatent period, survival and mortality). We finally isolated proteins from mice infected by the isolates, and assessed their proteomic profiles using mass spectrometry. We established putative resistance to 2.5 mg/kg suramin in the parasite Tbr EATRO-734. We established that Tbr EATRO-734 proliferated slower and has significantly enriched pathways associated with detoxification and metabolism of energy and drugs relative to Tbr EATRO-232. The Tbr EATRO-734 also has more abundantly expressed mitochondrion proteins and enzymes than Tbr EATRO-232. The suramin treatment failure may be linked to the relatively higher resistance to suramin in Tbr EATRO-734 than Tbr EATRO-232, among other host and parasite specific factors. However, the Tbr EATRO-734 appears to be less pathogenic than Tbr EATRO-232, as evidenced by its lower rate of parasitaemia. The Tbr EATRO-734 putatively surmount suramin challenges through induction of energy metabolism pathways. These cellular and molecular processes may be involved in suramin resistance in Tbr.
Keywords: Drug resistance; Drug sensitive, Trypanosoma brucei rhodesience; Suramin.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
The authors declare that no competing interests exist.
Figures



Similar articles
-
Differential virulence of Trypanosoma brucei rhodesiense isolates does not influence the outcome of treatment with anti-trypanosomal drugs in the mouse model.PLoS One. 2020 Nov 5;15(11):e0229060. doi: 10.1371/journal.pone.0229060. eCollection 2020. PLoS One. 2020. PMID: 33151938 Free PMC article.
-
Genetic diversity and population structure of Trypanosoma brucei in Uganda: implications for the epidemiology of sleeping sickness and Nagana.PLoS Negl Trop Dis. 2015 Feb 19;9(2):e0003353. doi: 10.1371/journal.pntd.0003353. eCollection 2015 Feb. PLoS Negl Trop Dis. 2015. PMID: 25695634 Free PMC article.
-
Impact of mass chemotherapy in domestic livestock for control of zoonotic T. b. rhodesiense human African trypanosomiasis in Eastern Uganda.Acta Trop. 2017 Jan;165:216-229. doi: 10.1016/j.actatropica.2016.08.022. Epub 2016 Aug 25. Acta Trop. 2017. PMID: 27570206
-
100 years since the publication of the suramin formula.Parasitol Res. 2023 Dec 7;123(1):11. doi: 10.1007/s00436-023-08027-7. Parasitol Res. 2023. PMID: 38057659 Free PMC article. Review.
-
Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis.Front Immunol. 2019 Jan 25;10:39. doi: 10.3389/fimmu.2019.00039. eCollection 2019. Front Immunol. 2019. PMID: 30740102 Free PMC article. Review.
Cited by
-
Structure-Activity Relationships, Tolerability and Efficacy of Microtubule-Active 1,2,4-Triazolo[1,5-a]pyrimidines as Potential Candidates to Treat Human African Trypanosomiasis.ChemMedChem. 2023 Oct 17;18(20):e202300193. doi: 10.1002/cmdc.202300193. Epub 2023 Jul 24. ChemMedChem. 2023. PMID: 37429821 Free PMC article.
-
Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies.Int J Mol Sci. 2023 Aug 7;24(15):12529. doi: 10.3390/ijms241512529. Int J Mol Sci. 2023. PMID: 37569903 Free PMC article. Review.
-
Systematic Review and Meta-Analysis on Human African Trypanocide Resistance.Pathogens. 2022 Sep 25;11(10):1100. doi: 10.3390/pathogens11101100. Pathogens. 2022. PMID: 36297157 Free PMC article. Review.
-
Structure-Activity Relationships, Tolerability and Efficacy of Microtubule-Active 1,2,4-Triazolo[1,5- a ]pyrimidines as Potential Candidates to Treat Human African Trypanosomiasis.bioRxiv [Preprint]. 2023 Mar 11:2023.03.11.532093. doi: 10.1101/2023.03.11.532093. bioRxiv. 2023. Update in: ChemMedChem. 2023 Oct 17;18(20):e202300193. doi: 10.1002/cmdc.202300193. PMID: 36945407 Free PMC article. Updated. Preprint.
References
-
- Alsford S., Field M.C., Horn D. Receptor-mediated endocytosis for drug delivery in African trypanosomes: fulfilling Paul Ehrlich's vision of chemotherapy. Trends Parasitol. 2013;29(5):207–212. - PubMed
-
- Antoine-Moussiaux N., Saerens D., Desmecht D. Flow cytometric enumeration of parasitaemia and haematologic changes in trypanosoma-infected mice. Acta Trop. 2008 Aug;107(2):139–144. - PubMed
-
- Apted F.I.C. Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Eastern hemisphere. Pharmacol. Ther. 1980;11:391–413. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases